REGENXBIO Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
REGENXBIO Inc. (RGNX) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $500.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-26.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2020-02-26
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2019-12-31 was $1.10M.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2019-09-30 was $100.00K.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2019-06-30 was $300.00K.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2019-03-31 was $400.00K.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2019 was $500.00K.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2018 was $0.00.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2016 was $400.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $1.20M derived: sum of 2 quarters · filed 2020-02-26 | $1.50M derived: sum of 3 quarters · filed 2020-02-26 | $500.00K 10-K · filed 2020-02-26 | |
| 2019-09-30 | $100.00K 10-Q · filed 2019-11-05 | $400.00K derived: sum of 2 quarters · filed 2019-11-05 | -$600.00K 10-Q · filed 2019-11-05 | $800.00K derived: sum of 4 quarters · filed 2020-02-26 | |
| 2019-06-30 | $300.00K 10-Q · filed 2019-08-07 | $700.00K 10-Q · filed 2019-08-07 | $700.00K derived: sum of 3 quarters · filed 2020-02-26 | $700.00K derived: sum of 4 quarters · filed 2020-02-26 | |
| 2019-03-31 | $400.00K 10-Q · filed 2019-05-07 | $400.00K derived: sum of 2 quarters · filed 2020-02-26 | $400.00K derived: sum of 3 quarters · filed 2020-02-26 | $400.00K derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $0.00 derived: sum of 2 quarters · filed 2020-02-26 | $0.00 derived: sum of 3 quarters · filed 2020-02-26 | $0.00 10-K · filed 2020-02-26 | |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | $0.00 derived: sum of 3 quarters · filed 2020-02-26 | $0.00 derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-02-26 | $0.00 derived: sum of 3 quarters · filed 2020-02-26 | $0.00 derived: sum of 4 quarters · filed 2020-02-26 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $0.00 derived: sum of 2 quarters · filed 2020-02-26 | $0.00 derived: sum of 3 quarters · filed 2020-02-26 | $0.00 10-K · filed 2020-02-26 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | $400.00K derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 | $400.00K derived: sum of 3 quarters · filed 2019-02-27 | $400.00K derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-08 | $400.00K derived: sum of 2 quarters · filed 2019-02-27 | $400.00K derived: sum of 3 quarters · filed 2019-02-27 | $400.00K derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $400.00K derived: sum of 2 quarters · filed 2019-02-27 | $400.00K derived: sum of 3 quarters · filed 2019-02-27 | $400.00K 10-K · filed 2019-02-27 | $435.00K 10-K · filed 2017-03-07 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $0.00 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-08 | $0.00 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-06 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |